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Available online 08 December 2020COVID-19 due to novel Coronavirus was first reported in Wuhan, China. Nowadays, the Islamic Republic of Iran
stands among countries with high COVID-19 prevalence and high burden of disease. Since themedical resources
are limited, we aimed to identify the risk factors for patients developing critical conditions. This can help to im-
prove resource management and treatment outcomes. In this retrospective study, we included 12,677 patients
who were from 26 hospitals, supervised by Tehran University of Medical Sciences with signs and symptoms of
COVID-19, until April 12. University integrated IT systemwas adopted to collect the data. We performed Logistic
regression to evaluate the association between death in COVID-19 positive patients and other variables. Cough,
respiratory distress and fever were the most common symptoms in our patients, respectively. Cancer, chronic
lung diseases and chronic neurologic diseases were the strongest risk factors for death in COVID-19 patients.






Coronaviruses are a group of RNA-coated viruses that cause wide-
spread respiratory, intestinal, liver, and neurological diseases in humans
and other mammals and birds [1]. Until a fewmonths ago, six species of
Coronavirus were known as human pathogens. These include E 229,
OC43, NL63, and HKU1 viruses, which are very common and typically
cause cold symptoms in immunodeficient people [2]. The other two
types of Coronaviruses are acute respiratory syndrome (SARS-CoV)
and Middle East Respiratory Syndrome (MERS-COV), which are zoo-
notic in origin and are sometimes fatal [3].
In December 2019, a novel Coronavirus (COVID-19, SARS-CoV-2)
with zoonotic nature was reported in Wuhan, China [4,5]. Numerous
human factors including poor assessment of the possible risks of the
virus, the location of Wuhan city, the vastness of the communication
network of the people of this city and Chinese New Year, in addition
to the virus's characteristics, including its high rate of transmissiongy and Biostatistics, School of
ox: 14155-6446, Tehran, Iran.
. Mansournia).
en access article under the CC BY-NCthrough human-to-human contact through droplets and the incubation
period, caused the virus to spread rapidly from Wuhan all over China
and from China to other parts of the world [6–8].
Soon, on January 2020, the first case out of China was confirmed in
Thailand. By the end of January 2020, a rapid increase of cluster cases
happened around the world and WHO declared that this epidemic
was a public health emergency of international concern (PHEIC) [9]. In
Iran, the Ministry of Health announced positive results for corona tests
in two patients on February 19, 2020. Nowadays, COVID-19 is rapidly
spreading and fighting with it is a global challenge. There have been
more than 58 million confirmed cases of COVID-19 and more than
1,390,300 deaths, reported as of 18November 2020 [10]. Since the path-
ogen is new, our knowledge about the disease and its epidemiological
parameters is incomplete.
COVID-19 can affect anyone regardless of age, gender and race [11].
Despite the fact that anyone who has had close contact with infected
patients is susceptible to novel coronavirus, it is not predictable
whether they will become infected or not [12,13]. People can transfer
the disease before they become symptomatic and about 44% of the
transmission occurs in this period [14,15].
This disease can presentwith different symptoms from fever, cough,
shortness of breath, myalgia, diarrhea, loss of smell, taste and loss of-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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days in 90% of cases and after 15 days nearly all cases but viral shedding
continues for about 18 days [16–19]. Severe cases have 60 times more
viral load than mild cases and they may continue shedding the virus
for even 25 days [20]. However, some people do not develop symptoms
but can transfer the disease [21–23]. Younger people are more likely to
remain asymptomatic [21]. Older people and those with immunodefi-
ciency are more likely to develop severe illness [12,24]. Infection in se-
vere cases may lead to pneumonia, organ failure and death [12].
Th increasing number of people with COVID-19 has increased the
need for beds in intensive care units (ICUs) [25]. So far, very little re-
search has been done on the risk factors for hospitalization in ICU
wards and the mortality of patients with novel coronavirus. Some re-
searchers have indicated that male gender, age and comorbidities
such as ischemic heart disease, diabetes and hypertension increases
are risk factors of mortality in COVID-19 patients [26]. However, risk
factors of developing critical conditions in these patients is still a
controversial issue.
Iran has had more than 866,000 confirmed cases and near 45,255
deaths until 18 November 2020 [10]. The number of cases is growing
and medical resources are limited [27]. Therefore, identifying the pa-
tients at higher risk for critical conditions helps to manage the disaster.
In this study, we described the characteristics of COVID-19 patients and
also assessed the risk factors formortality in the hospitals of TehranUni-
versity of Medical Sciences, Tehran, Iran.Table 1
The underlying diseases in all patients and COVID-19 positive patients.





Frequency Percentage Frequency Percentage
Diabetes Mellitus 855 6.74 236 11.24
Heart Disease 948 7.48 267 12.71
Hypertension 226 4.24 32 3.90Methods
In this study, we evaluated the information of 12,677 patients who
had been referred to the hospitals affiliated to Tehran University of
Medical Sciences, Tehran, Iran with COVID-19 symptoms from January
21 to April 12, 2020. The hospitals have been listed in the supplemen-
tary Table S1. We did not have any exclusion criteria in this study.
Data were obtained using the university's integrated MCMC (medi-
cal care monitoring center) system. We recorded age, gender, underly-
ing medical conditions (including hypertension, diabetes mellitus,
immunodeficiencies, heart disease, pulmonary disease, etc.), history of
close contact with infected people, COVID-19 symptoms (including
fever, cough, dyspnea, myalgia etc.), smoking, drug addiction, chest CT
scan reports and real-time reverse transcriptase polymerase chain reac-
tion (RT-PCR) results. Due to low and variable sensitivity of RT-PCR
(40–70%) we enrolled all patients with possible (typical signs and
symptoms for COVID-19 infection), probable (typical coronavirus
signs and symptoms with typical radiological findings) and definite
(suspicious signs and symptoms and positive RT-PCR test from respira-
tory secretions) diagnosis of COVID-19 infection. The diagnostic test
used in Iran was the PCR for respiratory tract secretions which were
sent to the virology section at School of Public Health, TUMS (which is
one of the reference virology labs in Iran). The results were sent to the
hospital every other day. PCR was taken from people who had 3 of the
following symptoms: fever, coughing, muscular pain and headache.
Since this was a retrograde study with minimal risk and we used
routine data collected from the patients, informed consent was not ob-
tained from the patients. This study was submitted and confirmed by
the ethics committee of Tehran University of Medical Sciences with
the ethical code of IR.TUMS.VCR.REC.1399.013.Chronic Kidney Disease 187 1.48 51 2.43
Asthma 161 1.27 24 1.14
Other Chronic Lung Diseases 166 1.31 31 1.48
Chronic Blood Disease 82 0.65 23 1.10
Chronic Liver Disease 55 0.43 10 0.48
Chronic Neurologic Diseases 50 0.39 12 0.57
Other Chronic Diseases 556 4.39 130 6.19
Cancer 204 1.61 40 1.90
HIV-AIDS 17 0.13 1 0.05
Immunodeficiency 43 0.34 7 0.33Statistical analysis
We used Stata version 14.2 for statistical analysis. Descriptive statis-
tics were presented by mean and standard deviation (SD) for continu-
ous variables, and frequencies and percentages for categorical
variables. Logistic regression was performed to evaluate the association
between death and other variables.2
Results
Weenrolled 12,677 people including 5742 (45.29%) females from26
hospitals, Tehran, Iran. Fourteen hospitals were educational and affili-
ated with Tehran University of Medical Sciences (TUMS) and the others
were private, charity or belonged to other organs but supervised by
TUMS during the COVID-19 pandemic. Themean (SD) age of the partic-
ipants was 50.01 (17.72). There were 60 pregnant (1.4%)women in this
population. Contact with COVID-19 positive patients were reported
from 1922 (15.16%) of the patients. Samples from 5895 (46.26%) pa-
tients were sent for RT-PCR. Among these, 2100 (35.62%) of the samples
were positive for COVID-19, 2413 (40.93%) were negative and 1382
(23.44%) of the test results were not ready till the end of the study.
Chest CT scan was performed for 854 patients and 683 (79.97%) of
themwere compatible with COVID-19 patterns. Peripheral capillary ox-
ygen saturation (SpO2) of the patients was evaluated at the time of ad-
mission and 4055 (31.99%) of them had SpO2 less than 93%.
Among the included patients, 10,684 (84.31%) were admitted to
general wards, 104 (0.82%) were isolated and 1885 (14.87%) were ad-
mitted to intensive care units (ICUs). During the hospitalization period
437 (3.45%) patients were intubated.
Table 1 summarizes patients' coexisting medical conditions. The
most frequent underlying diseases were heart disease and diabetes
mellitus with 948 (7.48%) and 855 (6.74%) patients, respectively.
Patients presented with different signs and symptoms. Table 2
shows the detailed information about patients' symptoms at the time
of admission. Themost common symptomswere cough (47.39%), respi-
ratory distress (34.42%) and fever (34.26%).
Frequency of smoking and drug abuse among our patients were 78
(1.46%) and 25 (0.47%), respectively.
During the study, we recorded 843 (6.65% of total population)
deaths that included 407 patients in general wards, one patient in iso-
lated room and 431 patients (3.40%) in ICUs. There were 322 (38.19%)
female and 521 (61.80%) male patients among deaths. Death rate
among intubated patients was 58.12% (254 patients). Mortality of test
positive patients was 376 (17.90%).
Logistic regression revealed that cancer (OR = 4.31, 95% CI:
2.29–8.11), chronic lung diseases (OR = 3.39, 95% CI: 1.64–6.98) and
chronic neurologic diseases (OR = 3.30, 95% CI: 1.04–10.47) are the
strongest risk factors for death in COVID-19 patients (Table 3). Table 3
shows underlying conditions that are associated with death in COVID-
19 patients. Complete results have been presented in the supplemen-
tary Table S2.
Patients who were intubated had the highest odds for death (OR =
13.96, 95% CI: 9.36–20.81). Loss of consciousness (OR = 8.34, 95% CI:
4.67–14.89) and respiratory distress (OR = 1.48, 95% CI: 1.18–1.86)
Table 2
Symptoms and signs in all and COVID-19 patients.
Symptoms and signs All patients
(n = 12,677)
COVID-19 positive
patients (n = 2100)
Frequency Percentage Frequency Percentage
Cough 6008 47.39 1024 48.76
Respiratory Distress 4363 34.42 765 36.43
Fever 4343 34.26 932 44.38
Muscular Pain 3644 28.74 582 27.71
Loss of Consciousness 240 1.89 51 2.43
Loss of Smell 130 2.44 10 1.22
Loss of Taste 14 0.11 2 0.10
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tality on patients' signs and symptoms have been presented in the sup-
plementary Table S3.
Discussion
Historically, one of the global challenges has always been emerging
pathogens. One of these challenges is Coronavirus [25,28]. In December
2019, the new Coronavirus has been introduced as the seventhmember
of the coronavirus family, which is different from both MERS-CoV and
SARS-CoV and infects humans [3]. Iran is currently fifteenth in terms
of statistics and the number of deaths in the world (until 18 Nov
2020) [10]. Due to growing number of the cases and limitedmedical re-
sources, early identification of the patients at higher risk for critical con-
ditions is necessary for delivering proper treatment and optimizing the
use of resources [27,29,30].
Based on a review published in June 2020, most common symptoms
are reported to be fever and cough [13]. A recent study from Iran, repre-
sents cough, fever and respiratory distress as the most prevalent symp-
toms [31]. These are consistent with our study as cough, respiratory
distress and feverwere reportedmore than other symptoms. Nowadays
the symptoms are divided into four types that represent the severity
level (mild, moderate, severe, critical) of the disease [32]. Fever may
be presented in all four types of the disease. However, respiratory symp-
toms and oxygen saturation are key indicators for differentiation of the
severity level [32].
Hypertension, diabetes mellitus and cardiovascular disease were
most common comorbidities, in previous studies [13,31]. Some comor-
bidities including hypertension, cardiovascular disease, chronic kidney
disease and cerebrovascular disease are associated with severity of the
disease [13]. Interestingly, the rate of HIV/AIDS as comorbidity was
very low in our study. A similar result has reported from another
studywhich evaluated the prevalence of COVID-19 signs and symptoms
among outpatient people who lived with HIV (PLWH) [32]. Among 200
PLWH, only one had confirmed diagnosis of COVID-19 infection [33].
This is possible that PLWH, especially whom receive antiretroviral
agents may be less susceptible to COVID-19 infection at least in sever
form of disease.
Case-fatality rate (CFR) is the total number of deaths divided by the
total number of infected patients. CFR depends on different factors.Table 3
Selecting underlying conditions associated with death in COVID-19 patients.
Variable Odds ratio 95% Confidence interval
Cancer 4.31 2.29–8.11
Chronic lung diseases 3.39 1.64–6.98
Chronic neurologic diseases 3.30 1.04–10.47
ICU admission 2.28 2.02–2.58
Age (10 years) 1.72 1.58–1.86
Heart disease 1.65 1.22–2.23
Gender 1.46 1.16–1.84
3
WHO estimated global CFR to be 3.8% [33]. CFR has a direct relation
with age and is higher in older patients [13]. In a report of 72,314 pa-
tients, overall case-fatality rate (CFR) was reported 2.3% but it was
higher in patients with cardiovascular disease, more than 70 years old,
diabetes, chronic lung disease, hypertension and cancer [34]. A retro-
spective cohort of Iranian patients showed 24.4% in-hospital mortality
rate in 30 days [31]. In our study, mortality rate of COVID-19 patients
was 17.9% and about half of these patients were in intensive care units.
A retrospective cohort study introduced a clinical risk score for
COVID-19 patients that evaluates the risk of developing critical condi-
tions including invasive ventilation, ICU admission and death [35].
Age, dyspnea, unconsciousness, cancer history, hemoptysis, direct bili-
rubin, neutrophil to lymphocyte ratio, lactate dehydrogenase, number
of comorbidities (Chronic obstructive pulmonary disease, diabetes, hy-
pertension, coronary heart disease, chronic kidney disease, immunode-
ficiency, cancer, cerebral vascular disease and hepatitis B) and chest
radiography abnormality, were included in this risk score. Our study
showed that cancer, chronic lung diseases, chronic neurologic diseases,
ICU admission, age (every 10 years), heart disease and male gender in-
crease the mortality rate in COVID-19 Patients.
Malignancies are known asmortality risk factor of lots of diseases in-
cluding COVID-19 [13,35,36]. Prevalence of COVID-19 may be lower in
patients with history of cancer [37]. The exact reason is unknown. How-
ever, cancer has an independent association with higher mortality of
these patients [37]. In this study, cancer had the highest odds ratio
among all other risk factors. Respiratory problems, especially chronic
lung disease worsen the patients' condition and increase mortality
[36,38]. A recent study showed that longer history of COPD results in
more negative outcomes and more death rate [38].
Literature has revealed that novel coronavirus in patients with pre-
existing neurological diseases is associated with poor outcomes
[39,40]. A study in Spain indicated that chronic neurologic disease is
among the most relevant comorbidities of COVID-19 [37].
Almost all of the researches showed that there is a relation between
age and developing critical condition in COVID-19 patients. The need for
intensive care unit (ICU) admission is higher in older patients [41].
Many researchers indicated that patients older than 60–65 years old
are at higher risk of mortality [13,36]. In a recent study, most of the
deaths were of patients with 70 to 89 years old [37]. In our study,
there was an increase in death rate with age.
Pre-existing cardiovascular problems especially coronary heart dis-
ease put the patient at great risk of developing fatal form of novel coro-
navirus disease [41]. Lots of studies have mentioned cardiovascular
diseases especially ischemic heart disease as a risk factor for mortality
in COVID-19 patients [13,26,36]. However, there are some studies that
did not find relation between cardiovascular diseases and mortality
rate [37].
Evidence suggests that mortality rate of novel coronavirus is higher
in men [36]. Meta-analysis studies showed that male gender is a risk
factor for disease progression and has an association with mortality
[42,43].Limitations
This study had some limitations. First, we collected data from one
province. However, because Tehran is capital, we had patients from all
over the country. Second, RT-PCR assay was not performed for all of
the patients. Third, we did not include laboratory variables and did
not perform multivariable logistic regression analysis as the laboratory
data were not available at the time of this study. Forth, some signs and
symptoms that recently were recognized as presentation for COVID-
19 (including diarrhea) were not included in our database. Fifth, some
inflated OR estimates and confidence limits in our results suggest the
possibility of sparse-data bias [44,45]. In fact, we could not assess the as-
sociation between some uncommon variables such as HIV, drug abuse,
A. Arman, M. Tajik, M. Nazemipour et al. Global Epidemiology 3 (2021) 100046immune deficiency, and loss of taste or smell with death due to an ex-
treme formal sparse-data bias known as separation [46].
Conclusion
This is one of the first studies that describes the risk factors of death
in novel coronavirus patients in Iran. We found higher mortality in pa-
tients with male gender, older age, cancer, heart disease, chronic lung
disease and chronic neurological disease.
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